文献速递胸部肿瘤支持与姑息治疗

接受普拉替尼治疗的RET融合阳性非小细胞肺癌患者中的肺外结核:韩国单中心同情用药经验

Extrapulmonary tuberculosis in patients with RET fusion-positive non-small cell lung cancer treated with pralsetinib: A Korean single-centre compassionate use experience.
PubMed 文献 · Eur J Cancer · 2021-11-06

在同情用药项目下,从2020年4月起共10例RET融合阳性非小细胞肺癌患者接受普拉替尼治疗,回顾性分析疗效与不良事件;9例可测量病灶患者中7例部分缓解,1例无可测量病灶患者临床缓解;大多数不良事件轻微可控,但2例在开始普拉替尼后不久发生肺外结核,经抗结核药物控制良好并继续普拉替尼治疗。

要点

  • 9例可测量病灶患者中7例达部分缓解,1例无可测量病灶患者达临床缓解。
  • 大多数不良事件轻微可控,2例发生肺外结核,经抗结核治疗控制良好。
  • 作者指出普拉替尼治疗期间发生结核值得注意,尚需大型研究证实因果关系与机制。

核心结论

  • 普拉替尼治疗期间发生结核值得注意,但尚需大型研究证实因果关系与潜在机制。

研究设计与样本

  • 韩国单中心同情用药项目,自2020年4月起共10例RET融合阳性非小细胞肺癌患者接受普拉替尼治疗,回顾性分析疗效与不良事件。

主要发现

  • 9例可测量病灶患者中7例达部分缓解,1例无可测量病灶患者也显示临床缓解。
  • 截至2021年1月8日,9例仍在接受普拉替尼治疗,仅1例停药。
  • 大多数不良事件轻微可控,但2例在开始普拉替尼后不久发生肺外结核,经抗结核药物控制良好,癌症病灶通过持续普拉替尼治疗得到管理。

临床怎么用

  • 作者认为普拉替尼治疗期间发生结核值得注意,并指出尚需大型研究证实因果关系与潜在机制。

局限性

  • 原文指出尚需大型研究证实因果关系与潜在机制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pralsetinib, an RET inhibitor, has shown a dramatic response in patients with RET fusion- or mutation-positive tumours in previous studies. As a novel target agent, however, the safety of pralsetinib remains to be determined. Herein, we present two cases of extrapulmonary tuberculosis (TB) that developed during pralsetinib therapy. METHODS: From April 2020, we administered pralsetinib to a total of 10 patients with RET fusion-positive non-small cell lung cancer under the compassionate use program. We retrospectively analysed the clinical efficacy of and adverse events related to pralsetinib therapy. RESULTS: Of the nine patients with measurable lesions, seven achieved a partial response. Additionally, one patient without measurable lesions also showed a clinical response. As of January 8, 2021, nine patients were still receiving pralsetinib therapy, while only one had discontinued pralsetinib therapy. Most adverse events were mild and manageable. However, two patients experienced extrapulmonary TB shortly after starting pralsetinib. The disease was well controlled with anti-TB medication, and the cancer lesions were managed through ongoing pralsetinib therapy. CONCLUSION: The development of TB during pralsetinib therapy is worth noting, although further large studies are required to demonstrate definitive relationship between causality and underlying mechanism.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Lee YP, Jeong BH, Eun Y, et al. Extrapulmonary tuberculosis in patients with RET fusion-positive non-small cell lung cancer treated with pralsetinib: A Korean single-centre compassionate use experience. Eur J Cancer. 2021. PMID: 34753013. doi:10.1016/j.ejca.2021.09.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。